Our Work


PinneyAssociates Commented to CDC on the National Health Interview Survey (NHIS) Revision

View PDF»

Judy Ashworth Commented to FDA on Future Opioid Analgesics and New Therapeutics for Pain and Addiction

View PDF»

What is known about the effects of nicotine on health

View PDF»

PinneyAssociates Commented to FDA on Abuse-Deterrent Formulations of CNS Stimulants

View PDF»

PinneyAssociates Comments that FDA Guidance on Drug Abuse and Dependence Will Minimize Occurrence and Risk of Substance Use Problems

View PDF»

Pinney Associates’ Scientific Abuse Potential Assessment of Kratom Finds Evidence of Public Health Benefit and Little Harm

View Press Release»

View 8-Factor Analysis»

PinneyAssociates Offers ALERRT® Methodology for In Vitro Assessment of Abuse-Deterrent Formulations

View PDF »


Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Shiffman S, Levine JG

Consumer understanding of prescription drug information: An illustration using an antidepressant medication.

Shiffman S, Gerlach KK, Sembower M, Rohay JM

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone

Ellis CN, Pillitteri J, Kyle TK, Ertischek MD, Burton SL, Shiffman S

Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT


The ALERRT® instrument: a quantitative measure of the effort required to compromise prescription opioid abuse-deterrent tablets.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling

Webster LR, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon M, Abrouk N, Medve R, Henningfield JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll S

An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Cone EJ, Giordano J, Weingarten B

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Reifler LM, Droz D, Bailey JE, Schnoll S, Fant RV, Dart RC, Bucher Bartelson B

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research

Gerlach KK, Dasgupta N, Schnoll S, Henningfield JE

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Setnik B, Cone EJ

Extreme work requirement of EG-001, an abuse-deterrent, extended-release morphine product, as demonstrated with the ALERRT® Visual Analog Scales.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

Sweeney CT, Sembower M, Ertischek MD, Shiffman S, Schnoll S

The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and Category 1 laboratory studies

Cone EJ, Buchhalter AR, Henningfield JE, Schnoll S